Phase III
Phase III Study: Perioperative Padcev & Keytruda Combo Significantly Improves Survival in Bladder Cancer
Padcev; Keytruda; enfortumab vedotin; pembrolizumab; phase III; bladder cancer; muscle-invasive bladder cancer; cisplatin-ineligible; perioperative; event-free survival; overall survival
Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies
Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy
Regenxbio Reports Consistent One-Year Benefit for DMD Gene Therapy RGX-202
Regenxbio; DMD; Duchenne muscular dystrophy; RGX-202; gene therapy; AFFINITY DUCHENNE trial; clinical trial; microdystrophin; biomarker; phase I/II; functional data
GSK Acquires Phase III-Ready Liver Drug Efimosfermin for Up to $2B to Enter MASH Arena
GSK; Boston Pharmaceuticals; efimosfermin alfa; Phase III; liver disease; MASH; SLD; drug acquisition; FGF21 analog
Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study
Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality
Lilly’s Tirzepatide Clears Phase III Cardiovascular Study on Heels of Novo Nordisk’s Semaglutide
Tirzepatide, Lilly, Phase III, Cardiovascular Study, Novo Nordisk, Semaglutide, Heart Failure, Obesity, Weight Loss
J&J, Legend’s Phase III Win Cements Carvykti as Earlier-Line Multiple Myeloma Treatment
Carvykti, Multiple Myeloma, Phase III, CARTITUDE-4, FDA Approval, BCMA-Targeted Therapy, Johnson & Johnson, Legend Biotech
NS Pharma’s Duchenne Muscular Dystrophy Therapy Viltepso Fails Confirmatory Trial
NS Pharma, Viltepso, Duchenne Muscular Dystrophy, Confirmatory Trial, Phase III, RACER53 Study, FDA Approval
Bayer’s New Drug Shows Promising Phase III Results for Menopause Symptom Relief
Bayer, Phase III results, menopause symptoms, drug, clinical trial, hot flashes, night sweats, hormone therapy
Sanofi’s Strategic Acquisition of Principia Bears Fruit with Rilzabrutinib’s Phase III Success
Sanofi, Principia, acquisition, Rilzabrutinib, Phase III, clinical trial, success, strategic investment, pharmaceutical industry, biotechnology, drug development.